RCT: Safety and efficacy of Eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures.
20 Jun, 2022 | 01:01h | UTCSafety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)